Professor of Pathology, Dana-Farber Cancer Institute

Pathology

Massimo Loda practices Pathology. Massimo Loda is a published doctor. He has 45 publications published. The most current publication "A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer." He accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.
• Advanced neuroendocrine prostate tumors regress to stemness.
• Paired exome analysis of Barrett's esophagus and adenocarcinoma.
• Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
• The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
• Development and Clinical Validation of an in situ Biopsy Based Multi-Marker Assay for Risk Stratification in Prostate Cancer.
• 26th Pezcoller Symposium: Cancers Driven by Hormones.
• HER2 as a target in invasive urothelial carcinoma.
• Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
• Association of prostate cancer risk variants with gene expression in normal and tumor tissue.
• A Novel Role for Microphthalmia-Associated Transcription Factor-Regulated Pigment Epithelium-Derived Factor during Melanoma Progression.
• AKT1 and MYC Induce Distinctive Metabolic Fingerprints in Human Prostate Cancer.
• Role of diet in prostate cancer: the epigenetic link.
• c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
• Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer.
• Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.
• 5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer.
• FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
• High-Resolution Array CGH and Gene Expression Profiling of Alveolar Soft Part Sarcoma.
• A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.
• De novo fatty acid synthesis at the mitotic exit is required to complete cellular division.
• Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis.
• A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
• The fat side of prostate cancer.
• ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
• Metformin--an Adjunct Antineoplastic Therapy--Divergently Modulates Tumor Metabolism and Proliferation, Interfering with Early Response Prediction by 18F-FDG PET Imaging.
• Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
• EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
• Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival.
• DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues.
• c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration...
• Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry.
• MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer.
• Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
• β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis.
• CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
• Cohort study of fatty acid synthase expression and patient survival in colon cancer.
• Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
• BRAF activation initiates but does not maintain invasive prostate adenocarcinoma.
• The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
• Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
• Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.
• Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.
• A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Schools

---

• University of Milan Faculty of Medicine And Surgery

• Ne Deaconess Hospital Harvard

• New England Med Center Tufts

Doctors Specialties

---

• Anatomic Pathology
• Pathology

Accepted Insurances

---

• Blue Card PPO
• Great West Healthcare-Cigna PPO
• First Health (Coventry Health Care) PPO
• Medicare MCR
• MultiPlan PPO
• PHCS Network PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO

Education

---

• Tufts Medical Center
• Beth Israel Deaconess Medical Center
• University of Milan Faculty of Medicine

Hospital

---

• Dana-Farber Cancer Institute
• Brigham and Women's Hospital

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1245306695
Last Name Of The Provider	LODA
First Name Of The Provider	MASSIMO
View All

Similar Doctors

---

	Dr. Shahinaz A. Bedri, MD This Doctor is OpenDoctor Recommended.
	Dr. Ben Z. Pilch, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Kristina M. Braaten, MD This Doctor is OpenDoctor Recommended.
	Dr. Peter M. Howley, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Gerlinde Wernig, MD This Doctor is OpenDoctor Recommended.
	Dr. Jason Schmidt, MD This Doctor is OpenDoctor Recommended.
	Dr. Catherine D. Chang, MD
	Dr. Mamta Gupta, MD
	Dr. Mark A. Rubin, MD This Doctor is OpenDoctor Recommended.
	Dr. Emily S. Reisenbichler, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles A. Parkos, MD
	Dr. Kirstine Y. Oh, MD This Doctor is OpenDoctor Recommended.
	Dr. Shuji Ogino, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Robert Daniel Odze, MD This Doctor is OpenDoctor Recommended.
	Dr. Danny A. Milner Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher A. French, MD This Doctor is OpenDoctor Recommended.
	Dr. Frank S. David, MD This Doctor is OpenDoctor Recommended.
	Dr. Li Chai, MD This Doctor is OpenDoctor Recommended.
	Dr. Seymour Rosen, MD
	Dr. Joel M. Henderson, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog